Lavendamycin antitumor agents: Structure-based design, synthesis, and NAD(P)H:quinone oxidoreductase 1 (NQO1) model validation with molecular docking and biological studies

Journal of Medicinal Chemistry

Volumn 51, Issue 11, 2008, Pages 3104-3115

  Hassani, Mary ^a   Cai, Wen ^c   Koelsch, Katherine H ^a   Holley, David C ^b   Rose, Anthony S ^c   Olang, Fatemeh ^c   Lineswala, Jayana P ^c   Holloway, William G ^c   Gerdes, John M ^b   Behforouz, Mohammad ^c   Beall, Howard D ^a  

^a UNIVERSITY OF MONTANA   (United States)

^b UNIVERSITY OF MONTANA   (United States)

^c BALL STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 N (2 FUROYL)NORLAVENDAMYCIN METHYL ESTER; 7 N ACETYLNORLAVENDAMYCIN BUTYLAMIDE; 7 N ACETYLNORLAVENDAMYCIN SEC BUTYLAMIDE; ANTINEOPLASTIC AGENT; LAVENDAMYCIN; LAVENDAMYCIN BETA HYDROXYETHYL ESTER; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (QUINONE);

ANTINEOPLASTIC ACTIVITY; ARTICLE; CRYSTAL STRUCTURE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; MOLECULAR DOCKING; PICTET SPENGLER REACTION; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CYTOCHROMES C; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MODELS, MOLECULAR; NAD(P)H DEHYDROGENASE (QUINONE); PROTEIN BINDING; STREPTONIGRIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44949195782     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701066a     Document Type: Article

References (69)

1. Skelly, J. V.; Sanderson, M. R.; Suter, D. A.; Baumann, U.; Read, M. A.; Gregory, D. S.; Bennett, M.; Hobbs, S. M.; Neidle, S. Crystal structure of human DT-diaphorase: A model for interaction with the cytotoxic prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). J. Med. Chem. 1999, 42, 4325-4330.
2. Danson, S.; Ward, T. H.; Butler, J.; Ranson, M. DT-diaphorase: A target for new anticancer drugs. Cancer Treat. Rev. 2004, 30, 437-449.
3. Lind, C.; Cadenas, E.; Hochstein, P.; Ernster, L. DT-diaphorase: Purification, properties, and function. Methods Enzymol. 1990, 186, 287-301.
4. Faig, M.; Bianchet, M. A.; Talalay, P.; Chen, S.; Winski, S.; Ross, D.; Amzel, L. M. Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: Species comparison and structural changes with substrate binding and release. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 3177-3182.
5. Li, R.; Bianchet, M. A.; Talalay, P.; Amzel, L. M. The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: Mechanism of the two-electron reduction. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8846-8850.
6. Ernster, L. DT Diaphorase. Methods Enzymol. 1967, 10, 309-317.
7. Ernster, L. DT Diaphorase: A historical review. Chem. Scripta 1987, 27A, 1-13.
8. Hassani, M.; Cai, W.; Holley, D. C.; Lineswala, J. P.; Maharjan, B. R.; Ebrahimian, G. R.; Seradj, H.; Stocksdale, M. G.; Mohammad, F.; Marvin, C. C.; Gerdes, J. M.; Beall, H. D.; Behforouz, M. Novel lavendamycin analogues as antitumor agents: synthesis, in vitro cytotoxicity, structure-metabolism, and computational molecular modeling studies with NAD(P)H:quinone oxidoreductase 1. J. Med. Chem. 2005, 48, 7733-7749.
9. Beall, H. D.; Liu, Y.; Siegel, D.; Bolton, E. M.; Gibson, N. W.; Ross, D. Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Biochem. Pharmacol. 1996, 51, 645-652.
10. Sun, X.; Ross, D. Quinone-induced apoptosis in human colon adenocarcinoma cells via DT-diaphorase mediated bioactivation. Chem.-Biol. Interact. 1996, 100, 267-276.
11. Lewis, A. M.; Ough, M.; Du, J.; Tsao, M. S.; Oberley, L. W.; Cullen, J. J. Targeting NAD(P)H:Quinone oxidoreductase (NQO1) in pancreatic cancer. Mol. Carcinog. 2006, 10.1002/mc.20199 .
12. Siegel, D.; Gibson, N. W.; Preusch, P. C.; Ross, D. Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. 1990, 50, 7483-7489.
13. Siegel, D.; Beall, H. D.; Senekowitsch, C.; Kasai, M.; Arai, H.; Gibson, N. W.; Ross, D. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry 1992, 31, 7879-7885.
14. Pink, J. J.; Planchon, S. M.; Tagliarino, C.; Varnes, M. E.; Siegel, D.; Boothman, D. A. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J. Biol. Chem. 2000, 275, 5416-5424.
15. Planchon, S. M.; Pink, J. J.; Tagliarino, C.; Bornmann, W. G.; Varnes, M. E.; Boothman, D. A. beta-Lapachone-induced apoptosis in human prostate cancer cells: Involvement of NQO1/xip3. Exp. Cell Res. 2001, 267, 95-106.
16. Walton, M. I.; Smith, P. J.; Workman, P. The role of NAD(P)H:quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun. 1991, 3, 199-206.
17. Swann, E.; Barraja, P.; Oberlander, A. M.; Gardipee, W. T.; Hudnott, A. R.; Beall, H. D.; Moody, C. J. Indolequinone antitumor agents: Correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. Part 2. J. Med. Chem. 2001, 44, 3311-3319.
18. Beall, H. D.; Winski, S.; Swann, E.; Hudnott, A. R.; Cotterill, A. S.; O'Sullivan, N.; Green, S. J.; Bien, R.; Siegel, D.; Ross, D.; Moody, C. J. Indolequinone antitumor agents: Correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity. J. Med. Chem. 1998, 41, 4755-4766.
19. Fisher, G. R.; Gutierrez, P. L. Free radical formation and DNA strand breakage during metabolism of diaziquone by NAD(P)H quinone-acceptor oxidoreductase (DT-diaphorase) and NADPH cytochrome c reductase. Free Radical Biol. Med. 1991, 11, 597-607.
20. Ngo, E. O.; Nutter, L. M.; Sura, T.; Gutierrez, P. L. Induction of p53 by the concerted actions of aziridine and quinone moieties of diaziquone. Chem. Res. Toxicol. 1998, 11, 360-368.
21. Siegel, D.; Gibson, N. W.; Preusch, P. C.; Ross, D. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): Role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. 1990, 50, 7293-7300.
22. Nemeikaite-Ceniene, A.; Dringeliene, A.; Sarlauskas, J.; Cenas, N. Role of NAD(P)H:quinone oxidoreductase (NQO1) in apoptosis induction by aziridinylbenzoquinones RH1 and MeDZQ. Acta Biochim. Pol. 2005, 52, 937-941.
23. Dehn, D. L.; Inayat-Hussain, S. H.; Ross, D. RH1 induces cellular damage in an NAD(P)H:quinone oxidoreductase 1-dependent manner: Relationship between DNA cross-linking, cell cycle perturbations, and apoptosis. J. Pharmacol. Exp. Ther. 2005, 313, 771-779.
24. Dehn, D. L.; Winski, S. L.; Ross, D. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1. Clin. Cancer Res. 2004, 10, 3147-3155.
25. Winski, S. L.; Hargreaves, R. H.; Butler, J.; Ross, D. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: Identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. Clin. Cancer Res. 1998, 4, 3083-3088.
26. Cresteil, T.; Jaiswal, A. K. High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem. Pharmacol. 1991, 42, 1021-1027.
27. Malkinson, A. M.; Siegel, D.; Forrest, G. L.; Gazdar, A. F.; Oie, H. K.; Chan, D. C.; Bunn, P. A.; Mabry, M.; Dykes, D. J.; Harrison, S. D.; Ross, D. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: Relationship to the response of lung tumor xenografts to mitomycin C. Cancer Res. 1992, 52, 4752-4757.
28. Mikami, K.; Naito, M.; Ishiguro, T.; Yano, H.; Tomida, A.; Yamada, T.; Tanaka, N.; Shirakusa, T.; Tsuruo, T. Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: Advanced tumors express greater levels of DT-diaphorase. Jpn. J. Cancer Res. 1998, 89, 910-915.
29. Rampling, R.; Cruickshank, G.; Lewis, A. D.; Fitzsimmons, S. A.; Workman, P. Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 1994, 29, 427-431.
30. Schlager, J. J.; Powis, G. Cytosolic NAD(P)H:(quinone-acceptor) oxidoreductase in human normal and tumor tissue: Effects of cigarette smoking and alcohol. Int. J. Cancer 1990, 45, 403-409.
31. Balitz, D. M.; Bush, J. A.; Bradner, W. T.; Doyle, T. W.; O'Herron, F. A.; Nettleton, D. E. Isolation of lavendamycin, a new antibiotic from Streptomyces lavendulae. J. Antibiot. (Tokyo) 1982, 35, 259-265.
32. Doyle, T. W.; Balitz, D. M.; Grulich, R. E.; Nettleton, D. E.; Gould, S. J.; Tann, C.; Moews, A. E. Structure determination of lavendamycin, a new antitumor antibiotic from Streptomyces lavendulae. Tetrahedron Lett. 1981, 22, 4595-4598.
33. Boger, D. L.; Yasuda, M.; Mitscher, L. A.; Drake, S. D.; Kitos, P. A.; Thompson, S. C. Streptonigrin and lavendamycin partial structures. Probes for the minimum, potent pharmacophore of streptonigrin, lavendamycin, and synthetic quinoline-5,8-diones. J. Med. Chem. 1987, 30, 1918-1928.
34. Behforouz, M.; Cai, W.; Mohammadi, F.; Stocksdale, M. G.; Gu, Z.; Ahmadian, M.; Baty, D. E.; Etling, M. R.; Al-Anzi, C. H.; Swiftney, T. M.; Tanzer, L. R.; Merriman, R. L.; Behforouz, N. C. Synthesis and evaluation of antitumor activity of novel N-acyllavendamycin analogues and quinoline-5,8-diones. Bioorg. Med. Chem. 2007, 15, 495-510.
35. Behforouz, M.; Cai, W.; Stocksdale, M. G.; Lucas, J. S.; Jung, J. Y.; Briere, D.; Wang, A.; Katen, K. S.; Behforouz, N. C. Novel lavendamycin analogues as potent HIV-reverse transcriptase inhibitors: Synthesis and evaluation of anti-reverse transcriptase activity of amide and ester analogues of lavendamycin. J. Med. Chem. 2003, 46, 5773-5780.
36. Fourie, J.; Oleschuk, C. J.; Guziec, F., Jr.; Guziec, L.; Fiterman, D. J.; Monterrosa, C.; Begleiter, A. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase. Cancer Chemother. Pharmacol. 2002, 49, 101-110.
37. Gane, P. J.; Dean, P. M. Recent advances in structure-based rational drug design. Curr. Opin. Struct. Biol. 2000, 10, 401-404.
38. Joseph-McCarthy, D. Computational approaches to structure-based ligand design. Pharmacol. Ther. 1999, 84, 179-191.
39. Kuntz, I. D. Structure-based strategies for drug design and discovery. Science 1992, 257, 1078-1082.
40. Suleman, A.; Skibo, E. B. A comprehensive study of the active site residues of DT-diaphorase: Rational design of benzimidazolediones as DT-diaphorase substrates. J. Med. Chem. 2002, 45, 1211-1220.
41. Erickson, J. A.; Jalaie, M.; Robertson, D. H.; Lewis, R. A.; Vieth, M. Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. J. Med. Chem. 2004, 47, 45-55.
42. Lyne, P. D. Structure-based virtual screening: An overview. Drug Discovery Today. 2002, 7, 1047-1055.
43. Kontoyianni, M.; McClellan, L. M.; Sokol, G. S. Evaluation of docking performance: Comparative data on docking algorithms. J. Med. Chem. 2004, 47, 558-565.
44. Asher, G.; Dym, O.; Tsvetkov, P.; Adler, J.; Shaul, Y. The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol. Biochemistry 2006, 45, 6372-6378.
45. Faig, M.; Bianchet, M. A.; Winski, S.; Hargreaves, R.; Moody, C. J.; Hudnott, A. R.; Ross, D.; Amzel, L. M. Structure-based development of anticancer drugs: Complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones. Structure 2001, 9, 659-667.
46. Winski, S. L.; Faig, M.; Bianchet, M. A.; Siegel, D.; Swann, E.; Fung, K.; Duncan, M. W.; Moody, C. J.; Amzel, L. M.; Ross, D. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, x-ray crystallographic, and mass spectrometric approaches. Biochemistry 2001, 40, 15135-15142.
47. Zhou, Z.; Fisher, D.; Spidel, J.; Greenfield, J.; Patson, B.; Fazal, A.; Wigal, C.; Moe, O. A.; Madura, J. D. Kinetic and docking studies of the interaction of quinones with the quinone reductase active site. Biochemistry 2003, 42, 1985-1994.
48. Cavelier, G.; Amzel, L. M. Mechanism of NAD(P)H:quinone reductase: Ab initio studies of reduced flavin. Proteins: Struct., Funct., Genet. 2001, 43, 420-432.
49. Chen, S.; Wu, K.; Zhang, D.; Sherman, M.; Knox, R.; Yang, C. S. Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: Combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling. Mol. Pharmacol. 1999, 56, 272-278.
50. Kende, A. S.; Ebetino, F. H. The regiospecific total synthesis of lavendamycin methyl ester. Tetrahedron Lett. 1984, 25, 923-926.
51. Boger, D. L.; Duff, S. R.; Panek, J. S.; Yasuda, M. Total synthesis of lavendamycim methyl ester. J. Org. Chem. 1985, 50, 5790-5795.
52. Behforouz, M.; Gu, Z.; Cai, W.; Horn, M. A.; Ahmadian, M. A highly concise synthesis of lavendamycin methyl ester. J. Org. Chem. 1993, 58, 7089-7091.
53. Behforouz, M.; Haddad, J.; Cai, W.; Arnold, M. B.; Mohammadi, F.; Sousa, A. C.; Horn, M. A. Highly efficient and practical syntheses of lavendamycin methyl ester and related novel quinolindiones. J. Org. Chem. 1996, 61, 6552-6555.
54. Fang, Y.; Linardic, C. M.; Richardson, D. A.; Cai, W.; Behforouz, M.; Abraham, R. T. Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin. Mol. Cancer Ther. 2003, 2, 517-526.
55. Phillips, R. M.; Naylor, M. A.; Jaffar, M.; Doughty, S. W.; Everett, S. A.; Breen, A. G.; Choudry, G. A.; Stratford, I. J. Bioreductive activation of a series of indolequinones by human DT-diaphorase: Structure-activity relationships. J. Med. Chem. 1999, 42, 4071-4080.
56. Jaffar, M.; Phillips, R. M.; Williams, K. J.; Mrema, I.; Cole, C.; Wind, N. S.; Ward, T. H.; Stratford, I. J.; Patterson, A. V. 3-Substituted-5- aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: Mechanism of activation and cytotoxicity in vitro. Biochem. Pharmacol. 2003, 66, 1199-1206.
57. Hendriks, H. R.; Pizao, P. E.; Berger, D. P.; Kooistra, K. L.; Bibby, M. C.; Boven, E.; Dreef-van der Meulen, H. C.; Henrar, R. E. C.; Fiebig, H. H.; Double, J. A.; Hornstra, H. W.; Pinedo, H. M.; Workman, P.; Schwartsmann, G. EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur. J. Cancer 1993, 29A, 897-906.
58. Phillips, R. M.; Jaffar, M.; Maitland, D. J.; Loadman, P. M.; Shnyder, S. D.; Steans, G.; Cooper, P. A.; Race, A.; Patterson, A. V.; Stratford, I. J. Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. Biochem. Pharmacol. 2004, 68, 2107-2116.
59. Kremer, W. B.; Laszlo, J. Comparison of biochemical effects of isopropylidine azastreptonigrin (NSC-62709) with streptonigrin (NSC-45383). Cancer Chemother. Rep. 1967, 51, 19-24.
60. SYBYL Molecular Modeling Software, version SYBYL 7.0; Tripos Inc.: St. Louis, MO, 2004.
61. Lemmen, C.; Lengauer, T. Time-efficient flexible superposition of medium-sized molecules. J. Comput.-Aided Mol. Des. 1997, 11, 357-368.
62. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
63. Skibo, E. B.; Gordon, S.; Bess, L.; Boruah, R.; Heileman, M. J. Studies of pyrrolo[1,2-alpha]benzimidazolequinone DT-diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive alkylation. J. Med. Chem. 1997, 40, 1327-1339.
64. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput.-Aided Mol. Des. 1997, 11, 425-445.
65. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 1982, 161, 269-288.
66. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
67. Muegge, I.; Martin, Y. C. A general and fast scoring function for protein-ligand interactions: A simplified potential approach. J. Med. Chem. 1999, 42, 791-804.
68. DeLano, W. L. The PyMOL Molecular Graphics System; versionPyMOL X11Hybrid; DeLano Scientific: San Carlos, CA, 2004.
69. Winski, S. L.; Swann, E.; Hargreaves, R. H.; Dehn, D. L.; Butler, J.; Moody, C. J.; Ross, D. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem. Pharmacol. 2001, 61, 1509-1516.